Join me in Music City June 6–7 for the Revolutionizing #AtopicDermatitis conference! Immerse in Nashville’s unique charm. Earn CME over two days of cutting-edge derm education. Use Silverberg at checkout for free registration https://t.co/LWq52tEXeg #RAD2025#gotoper
The Revolutionizing Atopic Dermatitis Conference in in Nashville, TN on June 6–7 this year! Join me and leading experts for two days of learning, networking, and AD insights. Use my code Silverberg for free registration! https://t.co/LWq52tEXeg #RAD2025#AtopicDermatitis#gotoper
Thrilled to share that Dr. Chovatiya will be joining me at Revolutionizing Atopic Dermatitis (RAD) on June 6-7 in Nashville, TN!
Use my code Silverberg for free registration and save your spot now: https://t.co/P2zPRRICbf
#RAD#AtopicDermatitis#gotoper
Join me at Revolutionizing Atopic Dermatitis (RAD) on June 6-7 in Nashville, TN! We will be discussing groundbreaking concepts in AD—where medicine meets Nashville’s rhythm.
Use my code Silverberg for free registration: https://t.co/P2zPRRICbf
#RAD#AtopicDermatitis#gotoper
You’re invited to the December virtual update on Revolutionizing Atopic Dermatitis! Get ready for CME/CE with practical patient-centered conversations and presentations on late-breaking research. Join us on December 8: https://t.co/LuB6qNP5rm @JonathanMd , @RajMDPhD
32) It appears that #topical application avoids the rare #toxicity seen with #systemic administration of #JAK-inhibitors. #AD is a pervasive problem in kids & adults and it's great to envision new, targeted, effective therapies!
31) There is growing evidence that JAK inhibitors are efficacious in #atopic_dermatitis, #alopecia_areata, #psoriasis, & #vitiligo. Additional evidence suggests that JAK inhibition may be broadly useful in dermatology, with early reports of efficacy in several other conditions.
25b) Significant itch reductions versus vehicle were reported within 12 hours of first application of 1.5% RUX (P < .05). Application site reactions were infrequent (<1%) and lower with RUX versus vehicle; none were clinically significant.
24a) Indeed, there are 2⃣: Topical #Ruxolitinib Evaluation in #Atopic_Dermatitis Study 1 (NCT03745638) & Study 2 (NCT03745651) #TRuE_AD enrolled patients aged ≥12 yrs with AD for ≥2 yrs, an Investigator's Global Assessment score of 2/3, and 3%-20% affected body surface area.
19) Follow-on Ph 3 studies yielded similar results. We'll address those TOMORROW and also talk about potential emerging topical #JAK inhibitors still to come. Meanwhile, which JAK receptor/s does #ruxolitinib inhibit?
10a) Thus #JAK inhibition can block the effects of multiple cytokines that are major players in #AD pathophysiology & ⬇️symptomatology. As per previous expert tweetorials from @DrStevenTChen@itchdoctor@Aller_MD (still available for CE/#CME credit at https://t.co/Pe6utbwPkZ)...
9) The #JAK-#STAT signaling pathway mediates effects of several key #cytokines on immune cells, keratinocytes, and peripheral sensory neurons that lead to inflammation and itch, including IL-4, IL-5, IL-13, IL31, IL-22, and TSLP
See https://t.co/kgmAkm9DMO.